OncoMatch/Clinical Trials/NCT07209241
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Is NCT07209241 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CART-EGFR-IL13Ra2 T cells for recurrent glioblastoma.
Treatment: CART-EGFR-IL13Ra2 T cells — This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: IDH1 wild-type
Prior therapy
Must have received: radiation therapy — first-line
glioblastoma, IDH-wildtype ... that has recurred following prior radiotherapy
Cannot have received: VEGF inhibitor (bevacizumab)
Receipt of bevacizumab within 3 months prior to physician-investigator confirmation of eligibility
Lab requirements
Kidney function
Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 ml/min and not on dialysis
Liver function
ALT/AST ≤ 3 x ULN; Total bilirubin ≤ 2.0 mg/dL, except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome (≤ 3.0 mg/dL)
Cardiac function
Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA
Adequate organ function defined as: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 ml/min and not on dialysis. ALT/AST ≤ 3 x ULN. Total bilirubin ≤ 2.0 mg/dL, except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome (≤ 3.0 mg/dL). Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07209241 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR amplification is a required biomarker for enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages